Objectives Tirzepatide Audit
ABCD is setting up a nationwide audit of tirzepatide (Mounjaro) in real clinical use in the UK. The aim will be to ascertain whether the experience in real clinical use matches the data from phase 3 clinical trials.
ABCD is setting up a nationwide audit of tirzepatide (Mounjaro) in real clinical use in the UK. The aim will be to ascertain whether the experience in real clinical use matches the data from phase 3 clinical trials.
Please note this programme is subject to change
The ABCD audit programme featured at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025) which was held on 19-22 March 2025 in Amsterdam, Holland.
Authors:
T. Hugh Jones, Karim Haider, Ahmed Haider, Umesh Dashora, Robert E, J. Ryder
Incidence and factors associated with restoration of hypoglycaemia awareness in adults with type 1 diabetes treated with hybrid closed-loop in the United Kingdom: Results from the ABCD audit.
Authors:
Alexandros L Liarakos, Thomas SJ Crabtree, Tomás P Griffin, Yew W Yap, Parth Narendran, Muhammad Ali Karamat, Geraldine Gallen, Sufyan Hussain, Jackie Elliott, Lalantha Leelarathna, Alistair Lumb, Robert EJ Ryder, Pratik Choudhary, Emma G Wilmot on behalf of all ABCD Closed-Loop Pilot audit contributors
Please note this programme is subject to change